Incyte
Preço: 108.53Empresa e modelo de negócios
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for oncology and other serious diseases. Its core products include Jakafi, a treatment for certain blood disorders, and other investigational therapies targeting various cancers. The company generates revenue mainly from product sales and collaborations with other pharmaceutical firms.
Perfil de investimento
The investment profile of Incyte is more aligned with growth investors, given its focus on innovative therapies and potential for future revenue increases. However, the current market conditions and performance metrics suggest a cautious approach. The stock may appeal to those with a medium to long investment horizon, prioritizing potential capital appreciation over immediate income. Liquidity is moderate, suitable for investors with basic to advanced experience.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 7.30 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- -15.5% ↓
- Surpresa de EPS
- 31.2% melhor que o esperado
- Volatilidade 20d
- 2.1% estável
Impacto da previsão
positivoAcompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-05 02:40 | Vender | Comprar | Mixed signals; revenue decline raises caution. |
| 2026-06-03 02:43 | Manter | Vender | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-24 02:42 | Vender | Manter | Weak fundamentals and mixed momentum signal caution. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-06-10 11:11 | H.C. Wainwright | Preço-alvo elevado | — → 140 | 103.23 |
| 2026-06-09 13:11 | Stifel Nicolaus | Atualizar | — → 123 | 103.07 |
| 2026-06-08 18:53 | Oppenheimer | Preço-alvo elevado | 90 → 107 | 100.64 |
Nada ainda